Key Points
- Insider sale: ClearPoint Neuro director Timothy Richards sold 5,415 shares on June 1 at an average price of $12.17, totaling about $65,900. After the sale, he still owned 87,198 shares.
- Stock and financial snapshot: CLPT shares were down 2.1% and opened at $12.37, with the company sporting a market cap of about $371 million. The stock has traded between $8.27 and $30.10 over the past year.
- Mixed fundamentals and analyst view: The company recently missed EPS expectations, posting a loss of $0.32 per share versus an expected loss of $0.28, though revenue slightly beat estimates. Analysts currently have a consensus Hold rating with an average price target of $18.00.
ClearPoint Neuro, Inc. (NASDAQ:CLPT - Get Free Report) Director Timothy Richards sold 5,415 shares of ClearPoint Neuro stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $12.17, for a total transaction of $65,900.55. Following the transaction, the director directly owned 87,198 shares of the company's stock, valued at $1,061,199.66. This represents a 5.85% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
ClearPoint Neuro Trading Down 2.1%
Shares of CLPT stock opened at $12.37 on Wednesday. ClearPoint Neuro, Inc. has a 12-month low of $8.27 and a 12-month high of $30.10. The company has a market capitalization of $370.98 million, a P/E ratio of -12.25 and a beta of 1.31. The firm has a 50-day moving average price of $10.73 and a 200 day moving average price of $12.54. The company has a quick ratio of 4.88, a current ratio of 5.79 and a debt-to-equity ratio of 2.63.
ClearPoint Neuro (NASDAQ:CLPT - Get Free Report) last announced its quarterly earnings results on Wednesday, May 13th. The company reported ($0.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by ($0.04). ClearPoint Neuro had a negative net margin of 71.57% and a negative return on equity of 140.96%. The firm had revenue of $12.13 million for the quarter, compared to the consensus estimate of $11.97 million. Research analysts forecast that ClearPoint Neuro, Inc. will post -1.05 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
CLPT has been the subject of several analyst reports. B. Riley Financial lifted their price target on shares of ClearPoint Neuro from $18.00 to $20.00 and gave the company a "buy" rating in a report on Wednesday, March 18th. Stifel Nicolaus assumed coverage on shares of ClearPoint Neuro in a research report on Friday, May 8th. They set a "buy" rating and a $16.00 target price on the stock. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of ClearPoint Neuro in a research report on Monday, April 20th. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Hold" and an average price target of $18.00.
View Our Latest Report on CLPT
Institutional Investors Weigh In On ClearPoint Neuro
A number of institutional investors and hedge funds have recently modified their holdings of the business. Bank of America Corp DE raised its stake in shares of ClearPoint Neuro by 37.4% during the first quarter. Bank of America Corp DE now owns 66,075 shares of the company's stock worth $601,000 after buying an additional 17,990 shares during the last quarter. Quantinno Capital Management LP raised its stake in shares of ClearPoint Neuro by 307.4% during the first quarter. Quantinno Capital Management LP now owns 51,947 shares of the company's stock worth $473,000 after buying an additional 39,195 shares during the last quarter. Bank of New York Mellon Corp raised its stake in shares of ClearPoint Neuro by 39.6% during the first quarter. Bank of New York Mellon Corp now owns 143,747 shares of the company's stock worth $1,308,000 after buying an additional 40,741 shares during the last quarter. Hsbc Holdings PLC bought a new stake in shares of ClearPoint Neuro during the first quarter worth approximately $129,000. Finally, SG Americas Securities LLC bought a new stake in shares of ClearPoint Neuro during the first quarter worth approximately $3,388,000. 30.08% of the stock is owned by institutional investors.
About ClearPoint Neuro
(
Get Free Report)
ClearPoint Neuro, Inc is a medical technology company specializing in the development and commercialization of an MRI-guided therapy platform for minimally invasive neurosurgical procedures. Headquartered in Cambridge, Massachusetts, the company's flagship ClearPoint® SmartFrame™ system enables surgeons to perform accurate and efficient intracranial interventions by providing real-time magnetic resonance imaging feedback. This technology is designed to improve patient safety and outcomes in treatments ranging from deep brain stimulation electrode placement to laser ablation of epileptic foci and brain tumors.
The ClearPoint System integrates hardware, software and imaging capabilities to guide instruments through the brain with submillimeter precision.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
